Sigyn Therapeutics

Sigyn Therapeutics, Inc. (OTC: SIGY) is a medical device company developing the Sigyn Therapy system — a blood purification device designed to reduce the pathological levels of inflammatory mediators that cause systemic inflammation and sepsis-related organ damage in critically ill patients. According to its website at sigyntherapeutics.com, the Sigyn Therapy device works by circulating a patient's blood through an extracorporeal blood purification system containing proprietary sorbent materials that selectively capture and remove pro-inflammatory cytokines, endotoxins, and other mediators of systemic inflammation from the bloodstream — potentially interrupting the inflammatory cascade that drives multi-organ failure and death in severe sepsis and other conditions characterized by pathological systemic inflammation. Sigyn's blood purification approach targets a critical unmet medical need, as sepsis remains one of the leading causes of death in intensive care units worldwide despite decades of pharmaceutical research.

Sigyn Therapeutics' therapeutic platform, described at sigyntherapeutics.com, is designed to complement rather than replace existing sepsis management approaches — including antibiotics, vasopressors, and supportive care — by providing a mechanical means of reducing the inflammatory burden in patients whose immune systems have generated pathologically elevated levels of inflammatory mediators that drive organ damage independent of the underlying infection. The device's extracorporeal blood purification approach draws on principles similar to dialysis and plasmapheresis — established extracorporeal treatment modalities widely used in ICUs — but targets the specific cytokine and endotoxin mediators of septic inflammation rather than waste products or autoimmune antibodies. Sigyn's proprietary sorbent materials are engineered to capture a broad spectrum of inflammatory mediators with the selectivity, capacity, and biocompatibility required for clinical use in critically ill patients.

Sigyn Therapeutics is pursuing regulatory clearance of its blood purification device through clinical evaluation programs designed to demonstrate safety and efficacy in sepsis and systemic inflammation patient populations. According to sigyntherapeutics.com, the company's development strategy involves both U.S. FDA and international regulatory pathways, with international markets potentially offering earlier clinical validation opportunities that can support the company's broader regulatory development objectives. Sigyn Therapeutics' combination of novel blood purification technology, sepsis and systemic inflammation therapeutic focus, extracorporeal device development approach, OTC-listed public company structure, and mission to address one of critical care medicine's most challenging unmet needs reflects its positioning as a development-stage medical device company pursuing a potentially important advance in sepsis treatment.